Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb delivered a significant earnings beat in Q2, driving shares up 20% since spring and boosting sector performance. Despite concerns about long-term EPS, strong Q2 results and improved guidance support a buy rating, with a valuation target near $76. BMY's technical chart shows bullish signals, including a potential golden cross and improved RSI momentum, indicating a favorable trend.

Bristol-Myers Squibb: A Better Earnings Outlook, Stronger Momentum Heading Into 2025

Celgene

Bristol-Myers Squibb Company (NYSE:BMY ) Wells Fargo 2024 Healthcare Conference September 6, 2024 12:00 AM ET Company Participants Adam Lenkowsky - Chief Commercialization Officer Conference Call Participants Mohit Bansal - Wells Fargo Cerena Chen - Wells Fargo Mohit Bansal All right. Good morning on a Friday.

Bristol-Myers Squibb Company (BMY) Wells Fargo 2024 Healthcare Conference (Transcript)

BMY has appreciated 26.56% since July but remains undervalued with a 4.8% yield, trading at less than 8 times 2025 earnings. Q2 earnings validated my thesis with a $680 million revenue beat and a $6.47 swing in non-GAAP EPS, showing strong profitability. Rate cuts will allow BMY to refinance nearly $50 billion in debt, reducing interest expenses and boosting margins.

Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research.

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research

Zenas BioPharma, which is developing immunology-based therapies, said on Friday it is targeting a valuation of as much as $689.7 million in its initial public offering in the United States.

Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO

AbbVie

Pfizer

Pharmaceutical (PPH) stocks have done relatively well this year. The closely watched iShares US Pharmaceutical ETF (IHE) stock has jumped by 16.5%, slightly beating the S&P 500 index, which has risen by 16.3%.

Pharma stocks analysis: Pfizer, Bristol-Myers Squibb, AbbVie

Bristol Myers Squibb (BMY) closed at $49.80 in the latest trading session, marking a -0.32% move from the prior day.

Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know

Bristol-Myers Squibb Company (NYSE:BMY ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 1:05 PM ET Company Participants Chris Boerner - Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks for joining us everybody.

Bristol-Myers Squibb Company (BMY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Recent results from Bristol Myers Squibb support an improving outlook. The company is benefiting from strong demand for its new medications.

2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High

HubSpot

An investment in these two stocks could pay off handsomely over the next five to 10 years. Bristol Myers is an established healthcare business with a portfolio of blockbuster drugs.

2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients.

Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb (BMY) closed at $49.95 in the latest trading session, marking a +0.46% move from the prior day.

Bristol Myers Squibb (BMY) Advances But Underperforms Market: Key Facts

Boston Properties

Chevron

Dominion Energy

Kraft Heinz

Altria

24/7 Wall St. Insights Dividend stocks are starting to outperform in the second half of 2024.

The Magnificent 7 Dividend Stocks Every Passive Income Investor Should Own

Gilead Sciences

Vertex Pharmaceuticals

Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.

Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday

Neurocrine Biosciences

Wednesday, Neurocrine Biosciences, Inc.  NBIX topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors

AT&T

Dividend stocks with less-than 75% payout ratios tend to outperform long term. The high-yield dividend payers AT&T, Bristol Myers Squibb, and Chevron stand out on this crucial measure.

3 High-Yield Dividend Stocks With Payout Ratios Below 75%

The benchmark S&P 500 index is way up over the past year, but some of its dividend-paying components haven't participated in the gains. Bristol Myers Squibb's dividend offers a high yield that could rise on the back of several new drugs with soaring sales.

2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024.

Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024

Bristol-Myers Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings.

Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO

Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.

Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma.

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.

Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated

CVS Health

Dow Inc

Bristol Myers Squibb doesn't sell anti-obesity drugs, but it can keep raising its dividend payout without them. Shares of Dow Inc. offer a yield above 5%, and there's a good chance the company can begin raising its payout again.

3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb will face major losses of patent exclusivity by 2029. BMS has launched a number of brand-new approvals to replace older products.

News for Bristol-Myers Stock (BMY)